Other Issues

CHPA strongly encourages FDA to provide further clarity regarding the appropriate human factors information in premarket submissions that involve a change from prescription use to over-the-counter use and associated changes from a predicate device as compared to modifications to a sponsor’s own device.

CHPA and members of our Dietary Supplements Committee appreciate the opportunity to comment on the recently released Draft Guidance outlining FDA’s approach to food allergen labeling.